^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD0120

    i
    Other names: AZD0120, GC012F, GC012, Dual CAR-BCMA-19, BCMA/CD19 dual-target CAR-T cell immunotherapy, AZD-0120, GC-012, GC-012F, AZD 0120, GC 012, GC 012F
    Company:
    AstraZeneca
    Drug class:
    CD19-targeted CAR-T immunotherapy, BCMA-targeted CAR-T immunotherapy
    Related drugs:
    22h
    AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) (clinicaltrials.gov)
    P1/2, N=182, Recruiting, AstraZeneca | N=80 --> 182
    Enrollment change
    |
    AZD0120
    26d
    A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) (clinicaltrials.gov)
    P3, N=508, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Apr 2029 --> Jul 2030
    Enrollment open • Trial completion date
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • AZD0120
    1m
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca | N=64 --> 40
    Enrollment change
    |
    AZD0120
    2ms
    AURORA: A Study of AZD0120 in Autoimmune Diseases (clinicaltrials.gov)
    P1, N=27, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AZD0120
    2ms
    DURGA-4: A Phase III, Open-label, Randomised, Multicentre Study to Evaluate AZD0120 in Participants With Relapsed Refractory Multiple Myeloma. (clinicaltrials.gov)
    P3, N=508, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • AZD0120
    3ms
    CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Tongji Hospital
    New P1 trial • IO biomarker
    |
    IFNG (Interferon, gamma) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • SDC1 (Syndecan 1) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
    |
    AZD0120
    3ms
    ZENITH: An Open-label Study of AZD0120 in Adults With Multiple Sclerosis (clinicaltrials.gov)
    P1, N=24, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | N=18 --> 24
    Enrollment open • Enrollment change
    |
    AZD0120
    3ms
    A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=18, Recruiting, Gracell Biotechnologies (Shanghai) Co., Ltd. | Phase classification: P1/2 --> P1 | N=118 --> 18
    Phase classification • Enrollment change
    |
    AZD0120
    4ms
    AURORA: A Study of AZD0120 in Autoimmune Diseases (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, AstraZeneca
    New P1 trial
    |
    AZD0120
    4ms
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=64, Recruiting, AstraZeneca | N=20 --> 64
    Enrollment change
    |
    AZD0120
    4ms
    Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis (clinicaltrials.gov)
    P1, N=9, Recruiting, Gracell Biotechnologies (Shanghai) Co., Ltd.
    New P1 trial
    |
    AZD0120
    5ms
    ZENITH: An Open-label Study of AZD0120 in Adults With Multiple Sclerosis (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, AstraZeneca
    New P1 trial
    |
    AZD0120